Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm > Drugs Affecting the Vascular System and Blood > Flashcards

Drugs Affecting the Vascular System and Blood Flashcards

1
Q

HMG-CoA reductase inhibitors (statins) - inhibit cholesterol synthesis in the liver

A

Prototype: - Antilipemic drug classifications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Bile acid sequestrants
Cholesterol absorption inhibitors
Fibrates
Vitamin B
Omega-3 fatty acids

A

Others to help lower cholesterol; sometimes on multiple drugs - Antilipemic drug classifications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Blocks HMG-CoA (enzyme helps facilitate synthesis of cholesterol) reductase from completing synthesis of cholesterol in the liver - effective way reduce cholesterol levels in pats with hyperlipidemia; block production of cholesterol

A

MoA: - HMG-CoA Reductase Inhibitors: Prototype: atorastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

At HS (highest rates cholesterol synthesis at HS) - most effective

A

Admin: - HMG-CoA Reductase Inhibitors: Prototype: atorastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

renal impairment, liver disease - works directly in liver so more dangerous affect to those who have underlying liver disease so if have impairment needs be cautious, heavy alcohol use, pregnancy category X - need lot cholesterol/essential for adequate fetal development

A

Caution: - HMG-CoA Reductase Inhibitors: Prototype: atorastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI effects (cramping, diarrhea, constipation), potential for liver damage (LFTs done periodically; q1yr), myalgias (muscle pain - mild (not notice them) to severe: severe = concerned; ask about muscle pains; in multiple areas of the body; present is sign statins causing muscle breakdown and release myoglobin and puts risk for developing rhabdomyolysis - prob is myoglobin put in bloodstream and sent to kidneys and really toxic to kidneys and put into AKI; must report immediately anything above mild); Toxic: rhabdomyolysis with AKI; lot have no issues

A

AE: - HMG-CoA Reductase Inhibitors: Prototype: atorastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

monitor liver and kidney function (toxicity) - LFTs and kidney func periodically to make sure not damaging liver, risk for AKI; teach to report myalgias for further assessment, no grapefruit juice (interacts where statins not metabolized - increases levels in blood - higher risk for rhabdomyolysis), lifestyle modification for high cholesterol

A

Nursing: - HMG-CoA Reductase Inhibitors: Prototype: atorastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Block platelet plug; affect where form platelet plug; inhibit platelets from sticking together - harder to form plug
More preventative measures - mild drugs that affect coag

A

Antiplatelet agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Block products of clotting cascade
More potent drugs; used for variety conditions; used for treatment blood clots

A

Anticoag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Inhibit platelet aggregation (COX inhibitor)

A

MoA: - Antiplatelet Agent/Salicylate: Prototype: Aspirin (ASA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prevention of MI, TIA, ischemic CVA in high-risk populations (primary or secondary prevention); most pats taking aspirin to prevent or at high risk of CV events

A

Indication: - Antiplatelet Agent/Salicylate: Prototype: Aspirin (ASA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

81-325 mg PO daily (81 mg is a “baby aspirin”)

A

Dose: - Antiplatelet Agent/Salicylate: Prototype: Aspirin (ASA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

GI irritation (N/V, epigastric pain); bleeding - GI bleeding, hematuria, easy bruising; tinnitus (with toxicity)

A

AE: - Antiplatelet Agent/Salicylate: Prototype: Aspirin (ASA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

take as directed, take with food, hold 1 week prior to procedure, monitor for s/s GI bleed (dark/bloody stools)

A

Nursing: - Antiplatelet Agent/Salicylate: Prototype: Aspirin (ASA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Inhibit platelet aggregation (alters signaling to platelets that crucial aiding in wanting to stick together)

A

MoA: - Antiplatelet Agent: Prototype: clopidogrel (Plavix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

prevent blood clot w/hx of MI, ischemic stroke, or PAD - prevent another CV event and prevent arterial blood clot for PAD pats; prevent blood clot with cardiac stent or bypass graft - prevent platelets sticking together to stent/graft - not long-term use, used until tissue grown over stent put in to decrease risk of clot

A

Indications: - Antiplatelet Agent: Prototype: clopidogrel (Plavix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Bleeding - major AE - not forming platelet plug means easier bleeding - can be fatal, flulike syndrome, dizziness, easy bruising, rash, pruritus

A

AE: - Antiplatelet Agent: Prototype: clopidogrel (Plavix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

hold 5 days prior to procedure - higher risk for more bleeding, bleeding precautions - soft bristel toothbrush used, electric razor, avoid injury/trauma

A

Nursing: - Antiplatelet Agent: Prototype: clopidogrel (Plavix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indication for medication (usually prevention blood clots associated with CV events, stent placement, PAD)
Clinical manifestations of bleeding/easy bruising notice with pats

A

Assessment:- Nursing considerations/antiplatelet agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Bleeding precautions
Avoid injury and falls
Hold prior to procedure/surgery
Educate patient on medication - imp; need understand sig of taking it

A

Interventions:- Nursing considerations/antiplatelet agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Disrupt clotting cascade making it difficult for blood to clot; inhibits clotting cascade; harder for blood to clot
Already have clot: used so blood clot not further extended, clot not move to other areas of body, body can take care of clot on its own; DOES NOT BREAK UP A CLOT

A

Anticoags:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Complication: ischemic stroke (embolus)
Treatment goals for disorder: prevent blood clot in atria
clots can form in atria because dysonchrous sequencing of squeeze so high risk for strokes
Drug therapy: warfarin, rivaroxaban

A

Chronic atrial fibrillation - Common Clotting disorders/comps/treatment goals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Complication: tissue hypoxia/death
Treatment goals for disorder: clot lysis; restore perfusion
Drug therapy: alteplase - thrombolytic - restores perfusion quickly

A

Ischemic stroke - Common Clotting disorders/comps/treatment goals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Complication: PE
Treatment goals for disorder: slow clot growth; inhibit propagation; inhibit new clots
fine if stays where is; prob if moves
Drug therapy: SQ heparin/enoxaparin, warfarin, rivaroxaban - anticoag; lot options for drugs

A

Deep vein thrombosis (DVT) - Common Clotting disorders/comps/treatment goals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Complication: tissue hypoxia/death
Treatment goals for disorder: slow clot growth; inhibit new glots; clot lysis; surgical
Serious condition
Drug therapy: IV heparin drip, alteplase - treatment variable

A

Pulmonary embolism (PE) - Common Clotting disorders/comps/treatment goals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Measure diff parts of clotting cascade
Ref range: 11-12.5 sec
Significance of pharmacology: prolonged: warfarin therapy
For warfarin
Time takes for blood to clot

A

Prothrombin time (PT) - Diagnostics lab: clotting time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Measure diff parts of clotting cascade
Ref range: 0.7-1.8
Significance of pharmacology: standard measure for PT; measurement for adjusting warfarin therapy
Therapeutic goal: 2.0-3.0
For warfarin
adjust warfarin dosing; standarized; therapeutic goal - harder for body form blood clot so want prolonged bleeding time; if under goal - means not have prolonged bleeding time
Time takes for blood to clot

A

International normalized ratio (INR) - Diagnostics lab: clotting time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Measure diff parts of clotting cascade
Ref range: 21-35 sec
Significance of pharmacology: prolonged: heparin therapy; measurement for adjusting heparin therapy
Therapeutic goal: 45-70 sec
Time takes for blood to clot

A

Activated partial thromboplastin time (aPTT) - Diagnostics lab: clotting time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

All anticoagulants have adverse effect of bleeding (non-fatal and fatal)
Reduce risk for injury and falls when given these drugs - fall because if hits their head; worry about a brain bleed
Implement bleeding precautions
Contraindications:
Drug-drug:

A

anticoags/thrombolytics: gen nursing considerations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Primary AE of drug - extension of MoA; high alert drugs due to bleeding; need give right doses to pats
Non-fatal: Hematuria, epistaxis, bruising
Fatal: Hemorrhagic stroke (bleeding in brain), internal bleeding, GI bleeding (older adult high risk)

A

All anticoagulants have adverse effect of bleeding (non-fatal and fatal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Pregnancy (except heparin/enoxaparin - molecules to large to pass through fetal/placental barrier so those are drugs of choice), hx bleeding disorders - exacerbates prob, hx of bleed/bleeding disorders - exacerbates prob, thrombocytopenia (low platelets - bleed easier)

A

Contraindications:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

antiplatelet agents (increase risk for bleeding because inhibit ability clot through diff pathways), NSAIDs (risk for bleeding, esp GI bleeding), herbals (all increase bleeding when taken together)

A

Drug-drug:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Disrupts clotting cascade; prolongs bleeding time

A

MoA: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Prevent or treat DVT (SQ - 3 injections); treat PE (IV drip)

A

Indications: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Pork allergy; Pork abstention religion (Judaism, Muslim) - heparin and enoxaparin (LMWH) derived from pigs

A

Contraindication: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Bleeding, heparin-induced thrombocytopenia (HIT - platelet counts lowered because heparin therapy), bruising at injection site (SQ)

A

AE: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Rotate/monitor injection sites for SQ (do not admin IM - absorb quicker and higher risk for suffering more AE), monitor platelet count; monitor aPTT (therapeutic 45-70 sec)

A

Nursing: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

protamine sulfate (heparin short half-life, stop infusion; reverse heparin; most OD on heparin on drip - usually just stop drip and short half-life get out body within hours so usually no need for reversal agent)

A

Reversal agent: - Indirect Thrombin Inhibitor (Anticoagulant): Prototype: Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Disrupts clotting cascade; prolongs bleeding time; molecule smaller than helparin and longer action time; adv: admin less often - just two injections

A

MoA: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

prevention or treatment of DVT

A

Indications: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Pork allergy; Pork abstention religion (Judaism, Muslim)

A

Contraindication: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

bleeding; bruising at injection site

A

AE: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

43
Q

Adm. deep SQ; do not aspirate or massage site; do not remove air bubble from prefilled syringe - seals medication in; rotate/monitor injection sites; monitoring of clotting time not necessary; not need monitor labs - affects clotting cascade in diff area; weight based doses; not admin with heparin

A

Nursing: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

44
Q

protamine sulfate

A

Reversal agent: - Low molecular weight heparin (Anticoagulant): Prototype: Enoxaparin (Lovenox)

45
Q

GI effects (n/v since PO), bleeding

A

AE: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

46
Q

antibiotics (monitor INR during therapy - causes prolonged bleeding time, more warfarin stays in bloodstream then need so higher risk for bleeding; draw this to monitor to make sure not too prolonged and not at risk for bleed), amiodarone (increased risk of bleeding), herbals (increased risk of bleeding)

A

Drug-drug: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

47
Q

Monitor PT/INR (therapeutic goal INR 2.0-3.0); see special considerations; first oral anticoagulant drug on market; time onset delayed; not admin with rivaroxaban; will bridge with enoxarpin as tyring to get to therapeutic level

A

Nursing: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

48
Q

vitamin K - liver K to work with and produces clotting factors - supercede action warfarin and allow blood clot faster and reverse action warfarin because too high

A

Reversal agent: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

49
Q

Interfere with hepatic synthesis of vitamin K-dependent clotting factors - liver synthesizes lot clotting factors and this interferes ones that are vit-K dependent; prolongs bleeding time; more for maintenance

A

MoA: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

50
Q

Chronic a-fib (most often used); artificial heart valves; prevent/treat DVT, PE - outpat option

A

Indications: - Vitamin K Antagonist (Anticoagulant): Prototype: Warfarin (Coumadin)

51
Q

Daily (usually in the evening or HS)
If INR is greater than 3.0: HOLD med and call prescribing provider - pat at risk for bleeding
Expect an order for Vitamin K if INR is greater than 4.0 (PO or SQ) - prescribed dependent on how high INR

A

Dosing: - Warfarin special considerations

52
Q

Dose change = next lab draw in 3 days - warfarin onset time is delayed; 36+ hours for changes to coag to take effect; dangerous if not check it again
Long term monitoring (INR stable) = INR drawn weekly or monthly

A

Lab draws: - Warfarin special considerations

53
Q

Teach patient to maintain consistent intake (avoid) vitamin K-containing foods (high intake may decrease warfarin effect) - since inhibiting vitamin K clotting factors; impacts INR so dose on intake taking

A

Diet: - Warfarin special considerations

54
Q

Kale
Collard greens
Spinach
Brussel sprouts
Broccoli
Asparagus
Sauerkraut
Soybeans
Edamame

A

Foods high in Vit K - GREEN

55
Q

St. John’s Wart
Garlic
Gingko
Ginger root
Chamomile

A

Herbals to avoid with Warfarin

56
Q

Disrupt clotting cascade; prolongs bleeding time

A

MoA: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

57
Q

PO

A

Route: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

58
Q

chronic a-fib; prevent DVT and PE

A

Indications: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

59
Q

bleeding

A

AE: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

60
Q

no blood monitoring required; no dietary considerations; much easier for pat take; risk for fatal bleeding less

A

Nursing: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

61
Q

Andexxa (coag factor Xa (recombinant))

A

Reversal agent: - Factor Xa Inhibitor (Anticoagulant): Prototype: rivaroxaban (Xarelto)

62
Q

Assessment:
Interventions:
Too much always let prescriber know and let HCP know what seeing

A

Initial management anticoag OD

63
Q

Clinical manifestations of bleeding and vital signs (HR/BP/O2 sat - unstable with internal bleeding) - esp if know given too much

A

Assessment: - Initial management anticoag OD

64
Q

Notify provider - let know VS and what seeing
Draw labs as ordered: Hemoglobin/hematocrit (worried about bleeding), platelets if on heparin therapy (bleeding, HIT); clotting times (PT/INR, aPTT)
Administer fluids (normal saline) and/or packed-red blood cells as ordered - blood transfusion
Administer reversal agent as ordered

A

Interventions: - Initial management anticoag OD

65
Q

Local fibrinolysis (acute clot lysis); break up the clot

A

MoA: - Thrombolytic Agent: Prototype: alteplase (Activase; tPA)

66
Q

Systemic: ischemic (embolic) stroke, PE, coronary thrombosis (MI); Local: central venous catheter occlusion - no major AE because not going into pat just sitting in line

A

Indications: - Thrombolytic Agent: Prototype: alteplase (Activase; tPA)

67
Q

bleeding, hypotension, bradycardia, tachycardia

A

AE: - Thrombolytic Agent: Prototype: alteplase (Activase; tPA)

68
Q

many; when used systemically sig assessment that appropriate for pat because can have detrimental effects because potent

A

Contraindications: - Thrombolytic Agent: Prototype: alteplase (Activase; tPA)

69
Q

Physical assessment with focus on cardiovascular and s/s bleeding
Labs: aPPT, PT/INR, H/H, platelets
Major Drug-drug: more than 1 anticoagulant/antiplatelet (ie; ASA, warfarin), herbal supplements, antibiotic therapy

A

Assessment - Drugs affecting blood coag/thrombolytic agent: nursing assessment/diagnosis/outcomes

70
Q

Risk for injury
Ineffective tissue perfusion

A

Nursing Diagnosis - Drugs affecting blood coag/thrombolytic agent: nursing assessment/diagnosis/outcomes

71
Q

Therapeutic effect with limited adverse effects (ie; absence of DVT, PE, stroke) - absence of blood clots
Client understanding of drug therapy, adverse effects, safety

A

Expected Outcomes - Drugs affecting blood coag/thrombolytic agent: nursing assessment/diagnosis/outcomes

72
Q

Bleeding precautions
Reduce risk for falls
Hold for procedures
Educate client: s/s bleeding; lab monitoring and diet if indicated

A

Nursing: drugs affecting blood coag: interventions

73
Q

Therapeutic response: absence of blood clots, restored perfusion
Adverse effects: monitor s/s bleeding most important!
Teaching (was it effective?)

A

Nursing: drugs affecting blood coag: eval

74
Q

The onset of warfarin is 36-48 hours. The patient will not be anticoagulated during this time. The diagnosis of a DVT warrants the need for more immediate anticoagulation to reduce the risk of complications, such as PE. The patient will be prescribed enoxaparin because it achieves anticoagulation quickly (onset 3-5 hours; duration 12 hours) and will provide anticoagulation until the warfarin’s action takes effect. When the patient’s INR is therapeutic on warfarin (2.0-3.0), the enoxaparin will be discontinued. This entire process is referred to as “bridging”.

A

The nurse on a medical-surgical unit is caring for a client who has just been diagnosed with a deep vein thrombosis (DVT) in the right lower extremity. The primary care provider has prescribed enoxaparin 70 mg SQ every 12 hours with the first dose STAT. In addition, the provider has prescribed warfarin 5 mg PO daily and a PT/INR draw in 3 days. Why has the primary care provider prescribed both medications simultaneously?

75
Q

In which situation could a thrombolytic agent be safely used?
A.CVA within the last 2 months
B.Acute MI within the last 3 hours
C.Recent, serious GI bleeding
D.Obstetrical delivery

A

Answer: B
Rationale: Blood clots can cause myocardial infarction and alteplase can be used to dissolve the clot. Other answers are contraindications to thrombolytic agents.

76
Q

Antiplatelet drugs would be useful in which of the following? Select all that apply.
A.Maintaining the patency of grafts
B.Decreasing the risk of fatal MI
C.Preventing re-infarction after MI
D.Dissolving a PE
E.Preventing thromboembolic stroke

A

Answer: A, B, C, E
Rationale: Antiplatelet drugs are used for the prevention of cardiovascular events. Thrombolytic agents are used to dissolve blood clots which are the cause of a pulmonary embolism.

77
Q

A patient who was treated in the hospital for a DVT in his left leg has been prescribed warfarin.
1.The patient asks, “will the warfarin dissolve the clot in my leg?” What is the nurse’s best response?

A

Warfarin will not dissolve the existing clot, but it will help prevent additional clot formation.

78
Q

A patient who was treated in the hospital for a DVT in his left leg has been prescribed warfarin.
2.The nurse plans to assess the patient’s lab work before administering the warfarin. What blood test(s) are important to monitor for patients taking warfarin, and what is the therapeutic range?

A

When a patient is taking warfarin, the nurse should closely monitor INR and PT levels to verify they are in normal range to prevent bleeding complications. Specifically, the therapeutic range for INR is between 2.0 to 3.0 depending upon the indication.

79
Q

A patient who was treated in the hospital for a DVT in his left leg has been prescribed warfarin.
3.The nurse knows that the patient will need to monitor his diet when taking warfarin. What dietary instructions should be provided to the patient?

A

Dietary instructions should be provided to maintain a consistent intake of foods high in vitamin K like leafy green vegetables. Daily changes in intake of foods that are high in vitamin K will influence the effectiveness of warfarin, as well as the patient’s INR levels used to maintain the warfarin levels in therapeutic range.

80
Q

A patient who was treated in the hospital for a DVT in his left leg has been prescribed warfarin.
4.The nurse plans to provide patient education regarding this newly prescribed medication. Outline education topics to cover with this high-risk medication.

A

Patient education should emphasize bleeding precautions, avoidance of NSAIDs and aspirin, the need for routine therapeutic monitoring, and when to call the provider with signs of increased bleeding

81
Q

A patient who was treated in the hospital for a DVT in his left leg has been prescribed warfarin.
5.What is the reversal agent for warfarin?

A

The reversal agent for warfarin is vitamin K

82
Q

RBCs carry O2
Decreased RBCs -> decreased Hgb synthesis -> decreased blood flow -> hemorrhage -> increased O2 consumption by tissues
Kidneys O2 sensor - sense decreased O2 and release EPO to stim production RBC

A

Review normal erythropoiesis

83
Q

provides Erythropoietin factor controlling rate of RBC production to stimulate body to produce RBC

A

MoA: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

84
Q

Disorders of RBC formation to decrease need for blood transfusions; renal failure (kidneys O2 sensory and have ESRD and kidneys not functioning not make RBC normally because missing stim from kidneys), antineoplastic treatments/agents (chemo for cancer; AE: decreasing RBC count)

A

Indications: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

85
Q

IV/SQ (mostly SQ)

A

Route: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

86
Q

Angina, caution in CHF

A

Contraindications: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

87
Q

Fatigue, bone pain, edema, hypertension (HTN) - too much med start overcrowd sys with volume, headache, fever (DVT, CVA, MI has occurred)

A

AE: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

88
Q

Monitor CBC weekly (track Hbg and RBC (both should go up but not too much) - dose depends on Hgb & indication), check VS (risk for HTN); analgesia for bone pain; goal Hgb above 10 - adequate levels so not symptomatic with anemia; hold if Hgb > 12 because not want overshoot too far

A

Nursing: - Anemia drugs: Erythropoiesis-Stimulating Agent: Prototype: Epoetin Alfa (Procrit)

89
Q

Replace iron losing to get more Fe stores; required for hemoglobin formation

A

MoA: - Anemia drugs: Agents for Iron Deficiency Anemia: Prototype: ferrous sulfate

90
Q

Iron deficiency, iron-deficiency anemia - replace Fe losing to help low Hgb and anemia occurring

A

Indications: - Anemia drugs: Agents for Iron Deficiency Anemia: Prototype: ferrous sulfate

91
Q

antacids/dairy reduce absorption sig - not getting Fe need

A

Drug-Drug/Food: - Anemia drugs: Agents for Iron Deficiency Anemia: Prototype: ferrous sulfate

92
Q

GI upset (HARD ON GI SYS), dark tarry stools (can look like upper GI bleed - look at med list and up to HCP on what want to do), constipation (teach: adequte fluids and exercise): see these common

A

AE: - Anemia drugs: Agents for Iron Deficiency Anemia: Prototype: ferrous sulfate

93
Q

monitor labs (Hgb, iron); take w/o food for best absorption - cannot if cannot tolerate given full glass water or something curb nausea; take with Vit C to increase absorption; Do not take within one hour of bedtime (GERD); Do not crush or empty capsules; reassess Hgb after 3 months initiating therapy - not frequent labs; Keep out of reach of children-fatal if overdosed (toxic to GI sys and cause multiorgan sys failure when very severe)

A

Nursing: - Anemia drugs: Agents for Iron Deficiency Anemia: Prototype: ferrous sulfate

94
Q

Replaces vitamin B12; required for Hgb formation

A

MoA: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: Cyancobalamin (Vitamin B12)

95
Q

B12 deficiency anemia, pernicious anemia

A

Indications: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: Cyancobalamin (Vitamin B12)

96
Q

Monthly SQ/IM (pernicious anemia); not PO since cannot absorb it originally

A

Dosage/Route: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: Cyancobalamin (Vitamin B12)

97
Q

rare; usually well tolerated; not usually OD on and cause Hgb way elevated; not worry about if take as prescribed

A

AE: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: Cyancobalamin (Vitamin B12)

98
Q

monitor labs for therapeutic response (Hgb, B12 if relevant); Teach pt. sudden discontinuation can cause anemia to return and irreversible nerve damage/depression; Pernicious anemia will need injections for lifetime because no cure

A

Nursing: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: Cyancobalamin (Vitamin B12)

99
Q

Required for erythropoiesis

A

MoA: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: folic acid

100
Q

Folic acid deficiency anemia (if diet changes ineffective), alcoholism/liver disease, pregnancy prevention of neural tube defects so take to ensure have enough

A

Indications: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: folic acid

101
Q

urine turns bright yellow

A

AE: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: folic acid

102
Q

monitor H/H, nutritional status, therapeutic response

A

Nursing: - Anemia drugs: Agents for Megaloblastic Anemias: Prototype: folic acid

103
Q

What instructions should the nurse include in teaching a client about ferrous sulfate? Select all that apply.
A.Take with milk to avoid GI upset
B.This medication may cause constipation
C.Keep away from children
D.Stools may turn green
E.Periodic blood tests needed to evaluate effect

A

Answer: B, C, E
Rationale: Ferrous sulfate will not turn stool green but can cause black, tarry stools. Dairy products can reduce the absorption of ferrous sulfate and should be avoided. Ferrous sulfate can cause constipation, is fatal to children if overdosed, and Hgb will be monitored for therapeutic effects.

Pharm (30 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions